Info Sheet for Technical description

No.0006

Organization

* Mandatoty fields

Name of Organization*	JUNTEN BIO CO.Ltd.	
Address, City, States, Zip, Country*	20F taisei Otemachi Bldg, 2-1-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004, JAPAN	
URL	https://juntenbio.co.jp/en/	
Brief Descriptions of Organization* (Approx. 100 words)	JUNTEN BIO, established in 2018 with commercialization rights from Juntendo University, is biotech company developing "Cell Therapy" that induces "Operational Tolerance" of the immune system to a specific antigen. Our approach is to induce T cells ex vivo to suppress only the immune response to the target antigen without any gene transfer, and then return the cells to the body to suppress the specific immune response. We have just started new challenge for development our cell therapy for complete elimination of immunosuppressant for "transplant rejection" with deceased donor liver transplantation in USA.	
new	Name*	NAHOKO UCHIDA
	Department* / Position	Product Development / Director
	E-mail* / TEL	nuchida@junytenbio.co.jp

What kind of technology do you want to offer? *

- ☑ **A.** Clinical Development Pipelines → Please see **Sheet【A】**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet【B】**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet【C】**

  * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☐ Yes — press release in preparation

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☑ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☑ Series A — JPY 1.2 Billion
- ☑ Series B — JPY 1.4 Billion
- ☑ Series C — JPY 0.8 Billion
- ☐ Series E or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☑ Yes	
☐ No	

Filled in by*	Nahoko Uchida
Date*	3rd September 2025

Ver.1.0

Sheet【A】 Clinical Development Pipelines

Info Sheet for Technical overview

No. A-0006

* Mandatoty fields

Title*

Antigen specific iTs (induced T cells with suppressing function) cell therapy

Development Phase*

☑	Basic Research	☐	Drug Discovery	☐	Pre-Clinical
☑	Clinical Trial (Phase I)	☑	Clinical Trial (Phase II)	☐	Clinical Trial (Phase III)
☐	Review	☐	Others		

Diesease Area*

☐	Cancer	☐	Central nervous system	☐	Ophthalmology
☐	Musculoskeletal	☐	Endocrine / Metabolism	☐	Cardiovascular
☐	Urogenital	☐	Digestive organ	☐	Blood
☐	Infection	☐	Dermatology	☑	Immunity
☐	Otolaryngology	☐	Respiratory	☐	Others

Description*

JUNTEN BIO believes our breakthrough technology has the potential to become a leading innovation in the field of immune regulation for Cell Therapy and Regenerative Medicine.
Today, patients who undergo organ transplantation must take lifelong immunosuppressants to prevent rejection, which leads to severe side effects and reduced quality of life. Our goal is to eliminate the need for lifelong immunosuppression in liver transplantation by enabling step-wise tapering and complete withdrawal of immunosuppressants.
In 2025, we initiated a new basic research program (JB-102) for deceased donor liver transplantation in collaboration with leading U.S. academia, following Phase I/II clinical trial(IIS,on-going) in Japan for living donor liver transplantation (JB-101).
Our approach is supported by compelling clinical results*: in a landmark study, 7 out of 10 liver transplant patients achieved long-term transplant tolerance for over 10 years through our donor antigen-specific induced T cells (iTs) therapy.
Beyond transplantation, iTs hold promise for application in autoimmune diseases, opening a broad pipeline for transformative therapies.
*Todo.S etal, Hepatology,2016 Aug;64(2):632-43.

Filled in by*	Nahoko Uchida
Date*	3rd September 2025